The study, which spans clinical sites in South Korea and the United States, includes a diverse cohort of 104 participants. The demographic breakdown shows 55 patients from South Korea and 49 from the U.S., with 68.3% of the total group receiving concurrent antifibrotic therapy. Functional assessments revealed a mean forced vital capacity of approximately 77% predicted and a mean diffusing capacity of the lungs for carbon monoxide of 51% predicted.

Bersiporocin functions by selectively inhibiting prolyl-tRNA synthetase, a mechanism designed to reduce collagen accumulation. By including both patients on background therapy and those who are treatment-naive, the trial mirrors real-world clinical environments. Professor Moo Suk Park of Severance Hospital noted that this baseline profile provides the necessary context to evaluate the drug’s future efficacy and safety outcomes. Daewoong Pharmaceutical anticipates releasing top-line results in the first half of 2027, bolstered by the drug’s existing Fast Track and Orphan Drug designations from the FDA and EMA.